Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 20/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457398 | 0.98 | TTK (0.46) | TTK | |
| SCHEMBL457094 | 0.98 | TTK (0.46) | TTK | |
| SCHEMBL462456 | 0.98 | TTK (0.46) | TTK | |
| SCHEMBL10279486 | 0.87 | ERN1 (0.47) | TTK | |
| SCHEMBL17590076 | 0.87 | ERN1 (0.47) | TTK | |
| SCHEMBL17425377 | 0.85 | ERN1 (0.47) | TTK | |
| SCHEMBL457528 | 0.85 | ERN1 (0.47) | TTK | |
| SCHEMBL457529 | 0.85 | ERN1 (0.47) | TTK | |
| SCHEMBL458383 | 0.83 | TTK (0.55) | TTK | |
| SCHEMBL455121 | 0.82 | TTK (0.51) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014020041-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-06 | — | — | WO | claimed |
| US-9255100-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| EP-2614063-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2614063-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |